Inga Mandac-Smoljanovic, MD, PhD

Clinical Hospital Merkur, Croatia

Poster(s):

• 1527 - Ibrutinib can be effective even at the lowest dose after 10 years of treatment

• 1529 - Prevalence of BTK, PLCG2, and BCL2 mutations in CLL patients in Croatia - KROHEM study